Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Treating primary tumor doesn’t improve OS in stage IV breast cancer

Key clinical point: Locoregional therapy does not offer a survival benefit in patients with metastatic breast cancer treated with optimal systemic therapy.

Major finding: The median overall survival was 54 months, both for patients who received continued systemic therapy and for those who received early local therapy.

Study details: A phase 3 trial of 256 patients with stage IV breast cancer and an intact primary tumor.

Disclosures: The trial was supported by the National Cancer Institute and Canadian Cancer Society. Dr. Khan reported no conflicts of interest.

Citation:

Khan SA et al. ASCO 2020, Abstract LBA2.